| Literature DB >> 28521788 |
Zainul Amiruddin Zakaria1, Farah Hidayah Kamisan2, Maizatul Hasyima Omar3, Nur Diyana Mahmood2, Fezah Othman4, Siti Selina Abdul Hamid5, Muhammad Nazrul Hakim Abdullah4.
Abstract
BACKGROUND: The present study investigated the potential of methanolic extract of Dicranopteris linearis (MEDL) leaves to attenuate liver intoxication induced by acetaminophen (APAP) in rats.Entities:
Keywords: Dicranopteris linearis; Gleicheniaceae; Hepatoprotection; Methanol extract; Volatile compounds
Mesh:
Substances:
Year: 2017 PMID: 28521788 PMCID: PMC5437572 DOI: 10.1186/s12906-017-1781-5
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1Effect of MEDL on body weight of male (a) and female (b) ICR mice in acute oral toxicity. Values are expressed as mean ± S.E.M. (n = 5/group)
Haematology value of rats treated with single dose of Dicranopteris linearis extract
| Hematological parameters | Treatment | ||
|---|---|---|---|
| Control | 5000 mg/kg MEDL | ||
| Male | |||
| Haemoglobin | g/L | 133.80 ± 2.99 | 144.60 ± 7.53 |
| Total red blood cell | ×1012/L | 8.49 ± 0.08 | 8.75 ± 0.49 |
| Total white blood cell | ×109/L | 5.62 ± 0.68 | 8.06 ± 0.96 |
| Packed cell volume | L/L | 0.37 ± 0.01 | 0.36 ± 0.02 |
| Mean corpuscular volume | fL | 43.80 ± 0.74 | 41.40 ± 1.25 |
| Mean corpuscular Hb conc | g/L | 352.20 ± 3.40 | 369.00 ± 14.73 |
| Platelet count | ×109/L | 1365.00 ± 90.28 | 1691.00 ± 240.20 |
| Female | |||
| Haemoglobin | g/L | 137.60 ± 3.44 | 141.40 ± 5.80 |
| Total red blood cell | ×1012/L | 8.00 ± 0.26 | 8.05 ± 0.20 |
| Total white blood cell | ×109/L | 2.64 ± 0.46 | 5.50 ± 0.68* |
| Packed cell volume | L/L | 0.35 ± 0.01 | 0.32 ± 0.01 |
| Mean corpuscular volume | fL | 43.60 ± 1.03 | 40.20 ± 0.80* |
| Mean corpuscular Hb conc | g/L | 394.00 ± 13.11 | 406.80 ± 7.32 |
| Platelet count | ×109/L | 537.60 ± 131.50 | 363.20 ± 210.30 |
Values are mean ± S.E.M. for 5 rats in each group
*Statistically significant compared to control (P < 0.05)
Biochemistry value of rats treated with single dose of Dicranopteris linearis methanol extract
| Biochemical parameters | Treatment | ||
|---|---|---|---|
| Control | 5000 mg/kg MEDL | ||
| Male | |||
| Total protein | g/L | 50.62 ± 1.49 | 58.42 ± 2.06 |
| Total bilirubin | umol/L | 0.14 ± 0.02 | 1.30 ± 0.44 |
| Alkaline phosphatase (ALP) | U/L | 141.40 ± 14.82 | 156.80 ± 9.69* |
| Alanine transaminase (ALT) | U/L | 169.40 ± 39.95 | 201.70 ± 31.42 |
| Aspartate transaminase (AST) | U/L | 623.90 ± 246.20 | 801.40 ± 126.90 |
| Creatinine | umol/L | 28.20 ± 1.63 | 46.40 ± 3.01* |
| Female | |||
| Total protein | g/L | 54.96 ± 2.38 | 48.86 ± 2.26 |
| Total bilirubin | umol/L | 0.14 ± 0.02 | 1.38 ± 0.42* |
| Alkaline phosphatase (ALP) | U/L | 133.20 ± 17.71 | 177.00 ± 25.20 |
| Alanine transaminase (ALT) | U/L | 95.06 ± 17.71 | 101.60 ± 25.78 |
| Aspartate transaminase (AST) | U/L | 169.70 ± 30.53 | 552.40 ± 54.31* |
| Creatinine | umol/L | 25.60 ± 0.81 | 47.80 ± 2.44* |
Values are mean ± S.E.M. for 5 rats in each group
*Statistically significant compared to control (P < 0.05)
Fig. 2Photomicrographs of different organ from representative male ICR mice in acute oral toxicity: a) and g): liver, b) and h): kidney, c) and i): stomach, d) and j): lung, e) and k): heart, and f) and l): spleen, stained with haematoxylin and eosin (100×)
Effect of MEDL on body weight and liver weight in experimental rats
| Treatment | Dose (mg/kg) | Body weight (BW) (g) | Liver weight (LW) (g) | LW/BW (%) |
|---|---|---|---|---|
| Control | - | 208.70 ± 5.55 | 5. 85 ± 0.29 | 2.80 ± 0.07 |
| APAP treated rats | 219.50 ± 4.72 | 9.72 ± 0.15a | 4. 44 ± 0.43a | |
| Silymarin + APAP | 200 | 200.00 ± 4.67 | 6.94 ± 0.24ab | 3.47 ± 0.11ab |
| MEDL + APAP | 50 | 218.07 ± 3.19 | 7.83 ± 0.88ab | 3.59 ± 0.80ab |
| 250 | 224.10 ± 3.41 | 6.16 ± 0.51b | 2.75 ± 0.87b | |
| 500 | 218.64 ± 2.83 | 6.65 ± 0.87b | 3.04 ± 0.88b |
Values are expressed as means ± S.E.M. of six replicates
aSignificant different as compared to normal control, p < 0.05
bSignificant different as compared to negative control, p < 0.05
Effects of different treatments on serum liver biomarkers of experimental rats
| Treatment | Dose (mg/kg) | ALT (U/L) | AST (U/L) | ALP (U/L) |
|---|---|---|---|---|
| Control | - | 158.30 ± 2.86 | 95.13 ± 5.92 | 115.70 ± 6.99 |
| APAP control (neg) | 1714.00 ± 142.20a | 2266.00 ± 340.40a | 330.00 ± 42.35a | |
| Silymarin +APAP (pos) | 200 | 474.50 ± 82.17b | 690.90 ± 146.60b | 195.50 ± 11.06b |
| MEDL | 50 | 225.90 ± 77.18b | 309.50 ± 94.85b | 252.20 ± 45.72 |
| 250 | 479.00 ± 204.10b | 1184.00 ± 564.30b | 228.20 ± 36.76b | |
| 500 | 445.10 ± 66.73b | 786.60 ± 96.77b | 350.30 ± 41.33 |
Values are expressed as means ± S.E.M. of six replicates
aSignificant different as compared to normal control, p < 0.05
bSignificant different as compared to negative control, p < 0.05
Antioxidant enzyme activities in liver tissue of APAP- treated rats, SOD (U/g tissue) and CAT (U/g tissue)
| Treatment | Dose (mg/kg) | SOD | CAT | GSH (μM/mg protein) |
|---|---|---|---|---|
| Normal | - | 9.66 ± 0.38 | 114.80 ± 1.63 | 68.32 ± 1.19 |
| 10% DMSO + APAP | - | 3.99 ± 0.07a | 91.36 ± 1.27a | 29.77 ± 0.47 |
| Silymarin + APAP | 200 | 15.37 ± 0.35b | 109.50 ± 4.69b | 59.44 ± 0.95 |
| MEDL + APAP | 50 | 13.04 ± 0.16b | 115.40 ± 2.37b | 38.12 ± 0.71 |
| 250 | 11.29 ± 0.13b | 120.30 ± 1.09b | 53.11 ± 1.05 | |
| 500 | 11.57 ± 0.33b | 118.2 ± 0.81b | 63.83 ± 2.03 |
Values are expressed as means ± S.E.M. of six replicates
aSignificant different as compared to normal control, P < 0.05
bSignificant different as compared to negative control (10% DMSO + APAP), P < 0.05
Fig. 3Liver photomicrographs. a) Normal architecture of liver showed the central vein (CV) and hepatocytes (H). b) APAP- treated group, showed necrosis of the hepatocytes (N), steatosis (S) and also infiltration the inflammatory cells (IL). c) APAP- induced after pre-treatment with 200 mg/kg of Silymarin showed normal architecture of hepatocytes with mild microsteatosis. d) Pre-treatment with 50 mg/kg of MEDL also attenuated the histopathological changes by the APAP- induced hepatotoxicity showed mild steatosis. e) Pre-treatment with 250 mg/kg of MEDL showed moderate necrosis of the hepatocytes. f) APAP-induced hepatotoxic liver after pre-treatment with 500 mg/kg MEDL showing mild steatosis
Fig. 4UHPLC-ESI-HRMS chromatogram of MEDL in comparison to several traces of flavonoids identified in it
Fig. 5GCMS chromatogram shows the presence of at least 48 volatile compounds in MEDL
GCMS profile shows the volatile phytoconstiutents of MEDL
| No. of peak | Retention time (min) | Area (%) | Name of the compound |
|---|---|---|---|
| 1 | 4.139 | 17.52 | Triphenylphosphine oxide |
| 2 | 8.111 | 0.79 | Phenol, 2,6-bis(1,1-dimethylethyl) |
| 3 | 11.592 | 1.52 | 2-Hexadecen-1-ol, 3,7,11,15-tetramethyl-, [R-[R*,R*-(E)]]- |
| 4 | 11.843 | 0.43 | 1,3-Propanediol, 2,2-dibromo- |
| 5 | 12.026 | 1.68 | Benzo[a]naphthacene |
| 6 | 12.243 | 0.82 | Methyl hexadecatrienoate |
| 7 | 12.460 | 9.70 | Methyl palmitate |
| 8 | 12.723 | 1.10 | Methyl 3-(3,5-di-tert-butyl-4-hydroxyphen yl)propionate |
| 9 | 14.083 | 4.17 | Methyl linoleate |
| 10 | 14.152 | 13.43 | Methyl 9,12,15- octadecatrienoate |
| 11 | 14.306 | 0.96 | trans-Phytol |
| 12 | 14.346 | 1.69 | Methyl stearate |
| 13 | 15.558 | 0.94 | (5E,7E)-Dodecadienal |
| 14 | 15.821 | 0.26 | 1,1,3,3,5,5,7,7,9,9,11,11,13,13-te tradecamethyl-heptasiloxane |
| 15 | 17.433 | 0.36 | 2-Myristynoyl-glycinamide |
| 16 | 17.896 | 0.55 | 1,2-Benzisothiazole-3-acetic acid, methyl ester |
| 17 | 18.067 | 0.25 | Cyclotrisiloxane, hexamethyl- |
| 18 | 18.084 | 0.27 | 2,3,4-Trimethoxyphenylacetonitrile |
| 19 | 18.290 | 0.22 | 1,1,3,3,5,5,7,7,9,9,11,11,13,13-te tradecamethyl-heptasiloxane |
| 20 | 18.399 | 0.45 | 1,1,3,3,5,5,7,7,9,9, 11,11-dodecamethyl- hexasiloxane |
| 21 | 18.427 | 0.45 | 4,5-Dimethyl-2,2-diphenyl-2H-imidazole |
| 22 | 18.490 | 0.22 | Silicic acid, diethyl bis(trimethylsilyl) ester |
| 23 | 18.541 | 0.25 | Silane, trimethyl[5-methyl-2-(1-methylethyl)phenoxy]- |
| 24 | 19.210 | 1.08 | 1,3,5-Triazine, 2-chloro-4,6-bis(methylthio)- |
| 25 | 19.667 | 0.39 | Gibberellin A3 |
| 26 | 19.736 | 5,45 | Erucylamide |
| 27 | 19.844 | 1.37 | N-Methyl-1-adamantaneacetamide |
| 28 | 19.896 | 1.02 | 2,4,6-Cycloheptatrien-1-one, 3,5-bis-trimethylsilyl- |
| 29 | 20.467 | 1.79 | 3,3-Diisopropoxy-1,1,1,5,5,5-hexamethyltrisiloxane |
| 30 | 20.685 | 1.04 | Shikimic acid |
| 31 | 20.753 | 1.16 | 1,2-Benzenediol, 3,5-bis(1,1-dimethylethyl)- |
| 32 | 20.948 | 1.73 | Merochlorophaeic Acid |
| 33 | 21.439 | 0.87 | 1,3-dimethyl-4-azaphenanthrene |
| 34 | 21.479 | 1.99 | 1-Amino-1-ortho-chlorophenyl-2-(2-quinoxalinyl)ethane |
| 35 | 23.382 | 0.35 | 2-(Acetoxymethyl)-3-(methoxycarbonyl)biphenylene |
| 36 | 23.399 | 0.42 | 1,2-Dihydroanthra[1,2-d]thiazole-2,6,11-trione |
| 37 | 23.428 | 0.70 | 1,2-Bis(trimethylsilyl)benzene |
| 38 | 23.542 | 2.37 | 1,3-Bis(trimethylsilyl)benzene |
| 39 | 23.577 | 2.02 | 2-Methyl-3-phenylindole |
| 40 | 24.274 | 4.63 | 5,10-Dihexyl-5,10-diihydroindolo[3,2-b]indole-2,7-dicarbaldehyde |
| 41 | 25.348 | 0.20 | 2-Ethylacridine |
| 42 | 25.920 | 0.86 | 2,4-Cyclohexadien-1-one, 3,5-bis(1,1-dimethylethyl)-4-hydroxy- |
| 43 | 25.954 | 0.55 | 1,3-Bis(trimethylsilyl)benzene |
| 44 | 26.880 | 0.29 | Gibberellic acid |
| 45 | 28.257 | 2.58 | 4′ methyl-2 phenylindole |
| 46 | 28.292 | 0.48 | 5′-Methyl-2′-(trimethylsiloxy)acetophenone |
| 47 | 28.309 | 1.65 | 5-nitrobenzofuran-2-carboxylic acid |
| 48 | 31.784 | 7.98 | 3,4-Pyridinedicarboxylic acid, 6-(4-chlorophenyl)-, dimethyl ester |
Volatile compounds with anti-inflammatory and antioxidant activities
| Volatile compound | Reported pharmacological activity/activitiesa |
|---|---|
| Phenol, 2,6-bis(1,1-dimethylethyl) | • Anti-inflammatory [ |
| 2-Hexadecen-1-ol, 3,7,11,15-tetramethyl-, [R-[R*,R*-(E)]]- | • Anti-inflammatory [ |
| Methyl palmitate | • Antifibrotic [ |
| Methyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate | • Antioxidant [ |
| Gibberellin A3 | • Anti-inflammatory [ |
| N-Methyl-1-adamantaneacetamide | • Anti-inflammatory [ |
| Shikimic acid | • Anti-inflammatory [ |
aPharmacological activity/activities – only reports related to the antioxidant and/or anti-inflammatory activities of the respective compounds was cited